NewAmsterdam Pharma Co N.V.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss
| For the three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| (In thousands of USD, except per share amounts) | ||
| Revenue | 3,040 | 2,978 |
| Operating expenses: | ||
| Research and development expenses | 38,009 | 44,751 |
| Selling, general and administrative expenses | 23,451 | 27,152 |
| Total operating expenses | 61,460 | 71,903 |
| Operating loss | (58,420) | (68,925) |
| Other income (expense): | ||
| Interest income | 5,650 | 7,351 |
| Fair value change – earnout | — | 3,992 |
| Fair value change – warrants | 5,942 | 13,762 |
| Foreign exchange gains/(losses) | (1,613) | 4,293 |
| Loss before tax | (48,441) | (39,527) |
| Income tax expense | — | — |
| Loss for the year | (48,441) | (39,527) |
| Other comprehensive income/(loss) | ||
| Unrealized gain/(loss) on available-for-sale securities, net of tax | (572) | (33) |
| Total comprehensive loss for the year, net of tax | (49,013) | (39,560) |
| Net loss per ordinary share | ||
| Basic and diluted | $(0.40) | $(0.34) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.